The Center for Breakthrough Medicines (CBM) and the University of Pennsylvania's Gene Therapy Program (GTP) have signed a landmark collaboration agreement, to combine Penn's...
Psilera Inc. (“Psilera”), a Florida-based biotechnology company developing non-hallucinogenic derivatives of psychedelic compounds and outpatient delivery methods for the treatment of anxiety, substance abuse,...
UCB announced that it has entered into a global co-development and co-commercialization agreement with Novartis covering UCB0599, a potential first in class, small molecule,...
